{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T18:01:02Z","timestamp":1648663262728},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1097\/rhu.0b013e31821c0cae","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T17:57:41Z","timestamp":1355767061000},"page":"204-206","source":"Crossref","is-referenced-by-count":3,"title":["Febuxostat Efficacy in Allopurinol-Resistant Tophaceous Gout"],"prefix":"10.1097","volume":"17","author":[{"given":"Mitchell","family":"Uh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210207","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1136\/ard.2008.099713","article-title":"Dual energy computed tomography in tophaceous gout.","volume":"68","author":"Choi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R2-9-20210207","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1017\/S001216220100202X","article-title":"Prevalence of, and risk factors for, physical ill-health in people with Prader-Willi syndrome: a population-based study.","volume":"44","author":"Butler","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"R3-9-20210207","first-page":"37","article-title":"A case of Prader-Willi syndrome accompanied with a renal stone Japanese.","volume":"44","author":"Asanuma","year":"1998","journal-title":"Hinyokika Kiyo"},{"key":"R4-9-20210207","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4067\/S0034-98872009000200012","article-title":"Morbid obesity in an adolescent with Prader-Willi syndrome.","volume":"137","author":"Santos","year":"2009","journal-title":"Rev Med Chil"},{"key":"R5-9-20210207","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/art.1780290710","article-title":"Phosphoribosylpyrophosphate synthetase superactivity. A study of five patients with catalytic defects in the enzyme.","volume":"29","author":"Becker","year":"1986","journal-title":"Arthritis Rheum"},{"key":"R6-9-20210207","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1383-5742(00)00052-1","article-title":"The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases.","volume":"463","author":"Jinnah","year":"2000","journal-title":"Mutat Res"},{"key":"R7-9-20210207","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1053\/j.ackd.2006.01.008","article-title":"Genetic factors associated with gout and hyperuricemia.","volume":"13","author":"Bleyer","year":"2006","journal-title":"Adv Chronic Kidney Dis"},{"key":"R8-9-20210207","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11926-007-0041-y","article-title":"Uricase and other novel agents for the management of patients with treatment-failure gout.","volume":"9","author":"Sundy","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"R9-9-20210207","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM196802082780601","article-title":"An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency.","volume":"278","author":"Kelley","year":"1968","journal-title":"N Engl J Med"},{"issue":"pt A","key":"R10-9-20210207","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4684-4553-4_32","article-title":"Gout resistant to allopurinol: poor compliance or non-response.","volume":"165","author":"Simmonds","year":"1984","journal-title":"Adv Exp Med Biol"},{"key":"R11-9-20210207","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10067-005-0043-y","article-title":"Rasburicase treatment in severe tophaceous gout: a novel therapeutic option.","volume":"25","author":"Moolenburgh","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R12-9-20210207","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/S0021-9258(18)63065-0","article-title":"On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo3,4-dpyrimidines.","volume":"245","author":"Massey","year":"1970","journal-title":"J Biol Chem"},{"key":"R13-9-20210207","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase.","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"R14-9-20210207","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e31821c0cae","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:55:51Z","timestamp":1620971751000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201106000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31821c0cae","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}